Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LOXL2 siRNA is a small interfering RNA designed to silence the expression of Lysyl Oxidase-Like 2 (LOXL2). LOXL2 is an enzyme involved in the cross-linking of collagen in the extracellular matrix, which is often upregulated in various cancers and associated with fibrosis and metastasis. In the context of pancreatic cancer research, specifically studies conducted at Cold Spring Harbor Laboratory, silencing LOXL2 using RNA interference was found to unexpectedly increase tumor growth and metastasis in syngeneic orthotopic mouse models, suggesting that LOXL2 may have complex roles in the tumor microenvironment that differ across cancer types.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LOXL2 siRNA.